https://www.thebodypro.com/category/biktarvy-pro/tag/news

The Latest

doctor with trans patient

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand
illustration of person on cliff with arms raised as sun rises/sets

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner
Promo Image

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best Img

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.

By Paul E. Sax, M.D. for NEJM Journal Watch
Bictegravir Approved in the U.S. in New Integrase Inhibitor-Based Fixed-Dose Combination (Biktarvy) Img

Bictegravir Approved in the U.S. in New Integrase Inhibitor-Based Fixed-Dose Combination (Biktarvy)

On Feb. 7, 2018, the U.S. FDA approved a new fixed-dose combination (FDC) containing bictegravir, emtricitabine and tenofovir alafenamide (TAF).

By Simon Collins for HIV i-Base
Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017 Img

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017

Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...

By David Alain Wohl, M.D.